Insights On Drug Development

31. Linking Clinical Correlates To Cell Therapy Outcomes 6/9/2025

    Streamline cell therapy development by transforming complex cellular characteristics into a predictive, multiparametric metric that guides the selection of high-potential starting material.

32. Injection Site Reaction Screening Methodology 6/6/2025

    Optimize drug formulations for solubility at physiological pH to reduce injection site reactions, enable high-concentration dosing, and enhance patient comfort and compliance.

33. Part Three: Rapid LVV Titering Determination 6/6/2025

    Explore how a platform compares data to traditional qPCR, p24 ELISA, and TU assays in measuring both physical and functional titers.

34. Part Two: Overcoming Limits In LVV Titer Measurement 6/6/2025

    Learn how a platform streamlines LVV titer measurement, offering a faster and more efficient alternative to traditional methods and addressing key process development challenges.

35. Part One: Challenges In LVV Purification And Quantitation 6/6/2025

    Discover how a company is overcoming purification challenges and advancing scalable, GMP-ready LVV manufacturing for gene and cell therapies.

36. Navigating OOX Results: Effective Analysis, Management In CDMO Labs 6/5/2025

    By prioritizing the management of Out of Expectation (OOX) results within your CDMO laboratory, learn how you can ensure product integrity, patient safety, and unwavering regulatory compliance.

37. Analytical Techniques For Assessing Quality Of Therapeutic Proteins 6/5/2025

    Evaluating quality attributes of therapeutic proteins requires a strategic, regulation-compliant selection of analytical techniques that consider molecular characteristics and phase to ensure characterization.

38. Simplify CAR-T Cell Manufacturing With LNP-Mediated Delivery 6/3/2025

    Streamline CAR-T cell manufacturing with lipid nanoparticles delivering base editors to create fratricide-resistant, CD45-edited CAR45 T cells, which enables scalable, precise, and potent therapies for blood cancers.

39. Versatile Lipid Nanoparticle Platform For Efficient Gene Editing 6/3/2025

    Lipid nanoparticles enable efficient gene editing in hard-to-transfect cells like T-cells and blood stem cells, which offers scalable, clinically relevant methods for developing advanced therapies for cancer and rare diseases.

40. A New Look At Subcutaneous mAb Delivery Using Nanoformed Particles 6/3/2025

    A highly concentrated non-aqueous suspension of an IgG1 was developed using a patented platform. Review how the particle size of the mAb impacts the overall behavior of the drug product.